ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

3:00PM-4:30PM: Abstract Number: 1706

Multi-omic Study in Patients with SITRAME Syndrome

Abstracts: Innate Immunity: Molecular Insights Into Immune Dysregulation

3:00PM-4:30PM: Abstract Number: 1747

Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Best Day (RA Subpopulations)

3:00PM-4:30PM: Abstract Number: 1730

Osteoarthritis Is a Risk Factor for Inflammatory Arthritis in Cancer Patients Treated with Immune Checkpoint Inhibitors

Abstracts: Immunological Complications of Medical Therapy

3:00PM-4:30PM: Abstract Number: 1724

Performance of a Novel Cardiovascular Risk Calculator in Rheumatoid Arthritis

Abstracts: Health Services Research I

3:00PM-4:30PM: Abstract Number: 1740

Performance of Large Language Models in Rheumatology Board-Like Questions: Accuracy, Quality, and Safety

Abstracts: Professional Education

3:00PM-4:30PM: Abstract Number: 1702

Placental Developmental Defects in a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss

Abstracts: Innate Immunity: Molecular Insights Into Immune Dysregulation

3:00PM-4:30PM: Abstract Number: 1751

Precision Targeting of Autoreactive 9G4 B Cells in Systemic Lupus Erythematosus Using Engineered Chimeric Antigen Receptor (CAR)- and Chimeric T Cell Receptor (cTCR)-T Cells

Abstracts: SLE – Treatment I: Cellular Therapy

3:00PM-4:30PM: Abstract Number: 1759

Predictors of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis Receiving IL-17A Inhibitor or TNF Inhibitor Therapy over 2 Years: A Post Hoc Analysis of a Phase IIIb Study

Abstracts: SpA Including PsA – Treatment I

3:00PM-4:30PM: Abstract Number: 1729

Prophylaxis Against Pneumocystis Jerovecii Pneumonia for Patients with Systemic Autoimmune Diseases: Analysis of the Veterans Affairs Database

Abstracts: Immunological Complications of Medical Therapy

3:00PM-4:30PM: Abstract Number: 1718

Randomization to Holding versus Continuing (JAKi, IL17) and Autoimmune Patient Responses to COVID-19 Boosters: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study

Abstracts: Epidemiology & Public Health II

3:00PM-4:30PM: Abstract Number: 1721

Recombinant Zoster Vaccine Uptake in US Adults with Rheumatic Disease: A Mixed Methods Analysis

Abstracts: Health Services Research I

3:00PM-4:30PM: Abstract Number: 1737

RheumMadness 2024: The Practical Impact of the Practically Perfect Season

Abstracts: Professional Education

3:00PM-4:30PM: Abstract Number: 1734

Safety and Efficacy Data from a Phase I Trial of Umbilical Lining-Derived Stem Cells (ULSC) in Adult Dermatomyositis/Polymyositis

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I

3:00PM-4:30PM: Abstract Number: 1733

Safety and Efficacy of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I

3:00PM-4:30PM: Abstract Number: 1749

Safety and Long-term Efficacy of CD19-CAR T-cell Therapy in 30 Patients with Autoimmune Disease

Abstracts: SLE – Treatment I: Cellular Therapy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].